Hims & Hers Short Interest Nears All-Time High, Buy The Dip?

Hims & Hers Health (HIMS) shares have recently pulled back by 11.4%, leading to high short interest and trading at 65% of its 52-week high, despite a pre-planned CEO stock sale that is not considered a red flag. The company demonstrates robust fundamentals, including 73% annual revenue growth, a 76.2% gross profit margin, and nearly tripled EPS, supporting its premium valuation. While the average analyst price target is lower, a bold $68 target from Canaccord Genuity, coupled with $19 million in recent institutional buying, suggests contrarian investors see a significant opportunity for a short squeeze and rebound, viewing the current dip as a pricing mistake.

Analysis

Hims & Hers Health (HIMS) shares have recently experienced an 11.4% decline, now trading at 65% of their 52-week high, which has attracted significant short interest nearing $4 billion as of September 2025, representing 31.4% of the stock float. This elevated short positioning, partly fueled by a pre-planned $11 million CEO stock sale in August 2024 that is not considered a red flag, presents a potential short squeeze opportunity for contrarian investors.

The company's underlying fundamentals remain robust, characterized by 73% annual revenue growth and an industry-leading 76.2% gross profit margin. Net earnings per share nearly tripled year-over-year to 17 cents, supporting its current 59.3x P/E ratio, a premium to the medical sector's 29.6x. The subscription-based model ensures stable and predictable cash flow, which is beneficial for reinvestment and shareholder value.

Despite a consensus "Reduce" rating and an average price target of $38.92, a bold $68 price target from Canaccord Genuity suggests substantial upside, approximately 43% above the current $48.86 price. This bullish outlook is reinforced by $19 million in institutional buying over the past quarter, indicating that "smart money" perceives the recent dip as a pricing mistake. The current risk-to-reward ratio is deemed favorable for investors considering the stock's significant pullback from its highs.

Key Decisions for Investors

• Investors should assess the potential for a short squeeze given the high short interest and recent price pullback.
• Focus on HIMS's robust fundamental growth, including 73% annual revenue growth and 76.2% gross margin, as key value drivers.
• Monitor institutional buying activity and analyst price targets, particularly the $68 high forecast, for signs of continued positive momentum.
• Consider the pre-planned CEO stock sale as non-material to long-term confidence, prioritizing operational performance.